ClinicalTrials.gg
CompletedNCT02218463Updated Apr 23, 2025Results posted

Treatment of Prepubertal Labial Adhesions

An interventional study of Estradiol cream 0.01% and Cetaphil in Prepubertal Labial Adhesions, sponsored by Children's Mercy Hospital Kansas City. Completed at 1 site in United States. Open to female participants aged 3 Months to 12 Years. Per ClinicalTrials.gov, last updated 2025-04-23.

Sponsored by Children's Mercy Hospital Kansas City · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
3 Months to 12 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Vulvar Diseases with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Vulvar Diseases · United States.

Enrollment
7th of 11
43 · median 61
Started
2014
the only one that year
No phase
5 of 13
1 open now
Registered
3rd of 13
by date
Lead sponsor
1 of 13
Children's Mercy Hospital Kansas City

Among the 13 studies in Vulvar Diseases with a site in United States, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2014, is one of 5 with no phase, and was the 3rd registered.

Vulvar Diseases

21 studies on the registry are indexed under Vulvar Diseases; 6 are open to participants now.

Browse Vulvar Diseases studies →

Open to participants now

4 of the 13 studies in Vulvar Diseases with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Vulvar Diseases studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 3 Months to 12 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Vulvar Diseases with a site in United States, or all of them as a file.
02

Study summary

First-line treatment for labial adhesions in prepubertal girls has been topical estrogen. This study aims to evaluate an alternative and less costly option of treatment with potentially less side effects.

Primary Hypothesis:

There will be a difference in complete resolution of labial adhesions with topical estrogen with lateral traction as compared to an emollient with lateral traction.

Read the detailed description

The etiology of labial adhesions is unclear but appears to be related to hypoestrogenism in combination with vulvar irritation. For many years, first-line treatment for labial adhesions in prepubertal girls has been topical estrogen. With the use of topical estrogen, 50% of labial adhesions resolve in 2 to 3 weeks and most labial adhesions resolve with 6 weeks of treatment. However, because topical estrogen is systemically absorbed, its use is associated with side effects such as breast budding, vulvar hyperpigmentation, vaginal bleeding. There is a high risk of recurrence of labial adhesions of up to 35% after treatment with topical estrogen. In addition, topical estrogen is costly. Therefore, there continues to be controversy over the optimal treatment of labial adhesions in prepubertal girls.

Generally, for medical treatment of labial adhesions, topical estrogen is applied to the adhesion whist applying gentle lateral traction to promote separation of the labia. It is, therefore, plausible that the lateral traction applied to the adhesion site is what ultimately results in the separation of the labial fusion, while the use of estrogen improves healing after mechanical separation.

This is a single site, prospective, randomized, double-blinded study evaluating the comparative effectiveness of topical estrogen with lateral traction versus topical emollient with lateral traction for the treatment of labial adhesions in prepubertal girls.

03

Conditions studied

  • Prepubertal Labial Adhesions

Keywords

  • Vulvar disease, adhesions, topical therapy
  • Labial adhesions prepubertal girls
  • Labial agglutination
  • Labial fusion
04

Who can participate

Ages eligible
3 Months to 12 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prepubertal girls ages 3 months to 12 years with labial adhesions

Exclusion criteria

Exclusion Criteria:

  • Presence of underlying dermatologic conditions such as lichen sclerosis, severe atopic dermatitis, psoriasis or vitiligo
  • Presence of systemic conditions that can have vulvar manifestations such as Crohn's disease and Behçet disease
  • Presence of disorders requiring treatment
  • Previous surgical separation of labial adhesions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Active comparator
    Cetaphil

    Apply a pea-sized amount to the labial adhesion with lateral traction twice daily

    Drug: Cetaphil

  • Active comparator
    Estradiol Cream 0.01%

    Apply a pea-sized amount to the labial adhesion with lateral traction twice daily

    Drug: Estradiol cream 0.01%

Interventions

06

What researchers measure

Primary outcomes

  1. Complete Resolution of Labial Adhesion.

    The first assessment will be 3 weeks after initiation of treatment. The final assessment will be 6 weeks after initiation of treatment.

    Time frame: 3 weeks and 6 weeks

Secondary outcomes

  1. Composite Severity Scale of Labial Adhesion Over Time

    Response to treatment of labial adhesion is dependent not only upon the size of the adhesion but also the thickness. A more accurate measurement of response to treatment would, therefore, incorporate both measurements. For this study, the percentage of closure of the introitus at presentation was assigned an ordinal value as follows: 1=25%, 2=50%, 3=75%, and 4=100%. The degree of thickness of the labial adhesion was also measured in a similar fashion: 1=thin, 2=intermediate and 3= thick. Those that were resolved received a rating of 0 on both scales. A composite severity scale was created by multiplying the value assigned to the percentage of introital closure by that assigned to the thickness of the adhesion for each of the 3 study visits. The composite severity scale ranged from 0 to 12. This allowed a comparison of treatment effect between each group over time wherein a lower composite severity score corresponded to a less severe labial adhesion.

    Time frame: 3 weeks and 6 weeks

07

Results

Posted Nov 27, 2019

Participant flow

Participant flow — Overall Study
MilestoneCetaphilEstradiol Cream 0.01%
Started2122
Completed1819
Not completed33

Outcome measures

PrimaryComplete Resolution of Labial Adhesion.

The first assessment will be 3 weeks after initiation of treatment. The final assessment will be 6 weeks after initiation of treatment.

Time frame:
3 weeks and 6 weeks
Reported as:
Count of participants · Participants
Complete Resolution of Labial Adhesion.
ParticipantsCetaphilEstradiol Cream 0.01%
Complete Resolution of Labial Adhesion.2122
Statistical analysis
  • Cetaphil vs Estradiol Cream 0.01% · Fisher Exact · p = 0.206
SecondaryComposite Severity Scale of Labial Adhesion Over Time

Response to treatment of labial adhesion is dependent not only upon the size of the adhesion but also the thickness. A more accurate measurement of response to treatment would, therefore, incorporate both measurements. For this study, the percentage of closure of the introitus at presentation was assigned an ordinal value as follows: 1=25%, 2=50%, 3=75%, and 4=100%. The degree of thickness of the labial adhesion was also measured in a similar fashion: 1=thin, 2=intermediate and 3= thick. Those that were resolved received a rating of 0 on both scales. A composite severity scale was created by multiplying the value assigned to the percentage of introital closure by that assigned to the thickness of the adhesion for each of the 3 study visits. The composite severity scale ranged from 0 to 12. This allowed a comparison of treatment effect between each group over time wherein a lower composite severity score corresponded to a less severe labial adhesion.

Time frame:
3 weeks and 6 weeks
Reported as:
Mean · units on a scale
Composite Severity Scale of Labial Adhesion Over Time
units on a scaleCetaphilEstradiol Cream 0.01%
Baseline6.3 ± 3.16.2 ± 2.0
3 weeks2.3 ± 2.41.5 ± 1.7
6 weeks1.9 ± 2.11.6 ± 1.9
Statistical analysis
  • Cetaphil vs Estradiol Cream 0.01% · ANOVA · p = 0.0001
  • Cetaphil vs Estradiol Cream 0.01% · ANOVA · p = 0.370
  • Cetaphil vs Estradiol Cream 0.01% · ANOVA · p = 0.425

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetaphil—0/21 (0%)1/21 (4.8%)
Estradiol Cream 0.01%—0/22 (0%)1/22 (4.5%)
Most frequent other events
Most frequent other events
EventCetaphilEstradiol Cream 0.01%
Vulvar irritationSkin and subcutaneous tissue disorders1/211/22

Baseline characteristics

Age, Continuous
Age, Continuous(months)CetaphilEstradiol Cream 0.01%Total
Mean33 (5 to 84)26 (4 to 108)29 (4 to 108)
Sex: Female, Male
Sex: Female, Male(Participants)CetaphilEstradiol Cream 0.01%Total
Female212243
Male000
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)CetaphilEstradiol Cream 0.01%Total
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)CetaphilEstradiol Cream 0.01%Total
United States212243
% introital closure
% introital closure(participants)CetaphilEstradiol Cream 0.01%Total
25%101
50%549
75%4711
100%111122
Thickness of labial adhesion
Thickness of labial adhesion(Participants)CetaphilEstradiol Cream 0.01%Total
Thin549
Intermediate141731
Thick213
Urinary tract infection
Urinary tract infection(Participants)CetaphilEstradiol Cream 0.01%Total
Present022
Absent212041
Vulvovaginitis
Vulvovaginitis(Participants)CetaphilEstradiol Cream 0.01%Total
Present000
Absent212243

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Children's Mercy Hospitals & Clinics
    Kansas City, Missouri 64108, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of May 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2019, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2014
First posted
Aug 18, 2014
Start
Sep 2014
Primary completionActual
May 2016
CompletionActual
Jun 2016
Results first posted
Nov 27, 2019
Last update
Apr 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02218463
Collaborators
University of Missouri, Kansas City
Responsible party
Sponsor
First posted
Aug 18, 2014
Start date
Sep 2014
Primary completion
May 2016
Completion
Jun 2016
Results posted
Nov 27, 2019
Last update
Apr 23, 2025

Study contacts

Tazim Dowlut-McElroy, MD
principal investigator · University of Missouri, Kansas City
Julie L Strickland, MD, MPH
study director · University of Missouri-Kansas City; Children's Mercy Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Cetyl alcohol, propylene glycol, sodium lauryl sulfate non-lipid cleansing lotion

Start the discussion